Related Experiment Video
Updated: May 5, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
High-Fat Diet-Induced Diabetic Cardiomyopathy in Female Zebrafish: Cardiac Pathology and Functional Decline Mediated
Shuaiwang Huang1, Zhanglin Chen1, Haoming Li1
1College of Physical Education, Hunan Normal University, Changsha 410012, China.
Background:
Diabetic cardiomyopathy (DCM) is characterized by progressive cardiac dysfunction, metabolic dysregulation, myocardial fibrosis, and mitochondrial impairment. Existing animal models, such as streptozotocin (STZ)-induced models, suffer from high mortality and fail to replicate chronic metabolic dysregulation induced by high-fat diets (HFD), whereas HFD or HFD/STZ-combined rodent models require high maintenance costs. This study aimed to establish a zebrafish HFD-DCM model to facilitate mechanistic exploration and drug discovery.
Methods:
Eighty wild-type female zebrafish were divided into normal diet (N, 6% fat) and HFD (H, 24% fat) groups and fed the diet for 8 weeks. Metabolic phenotypes were evaluated using intraperitoneal glucose tolerance tests and insulin level analysis. Cardiac function was assessed by using echocardiography (ejection fraction, E peak). Structural, metabolic, and oxidative stress alterations were analyzed by histopathology (H&E, Masson, and Oil Red O staining), molecular assays (RT-qPCR, Western blotting), and mitochondrial structure/function evaluations (respiratory chain activity, transmission electron microscopy, and DHE staining).
Results:
HFD-fed zebrafish developed obesity, insulin resistance, and impaired glucose tolerance. Echocardiography revealed cardiac hypertrophy, reduced ejection fraction, and diastolic dysfunction. Excessive lipid accumulation, upregulated fibrosis/inflammatory markers, impaired mitochondrial respiration, elevated reactive oxygen species levels, and a disrupted redox balance were observed.
Conclusions:
We established a female zebrafish HFD model that recapitulates human DCM features, including hypertrophy, metabolic dysregulation, fibrosis, inflammation, and mitochondrial dysfunction. This model offers novel insights into DCM pathogenesis and serves as a valuable platform for mechanistic studies and targeted drug screening.
Insights
A new high-fat diet (HFD) zebrafish model effectively mimics diabetic cardiomyopathy (DCM) in females. This model aids in understanding DCM and discovering new drug therapies for metabolic heart disease.
Area of Science:
- Cardiovascular Research
- Metabolic Disease Models
- Zebrafish Models
Background:
- Diabetic cardiomyopathy (DCM) involves cardiac dysfunction, metabolic issues, fibrosis, and mitochondrial problems.
- Current rodent models have limitations like high mortality, failure to mimic chronic metabolic changes, or high costs.
- A need exists for a cost-effective and relevant model for DCM research.
Purpose of the Study:
- To establish a novel high-fat diet (HFD)-induced zebrafish model for diabetic cardiomyopathy (DCM).
- To enable better mechanistic exploration and drug discovery for DCM.
- To provide a suitable platform for studying metabolic dysregulation in cardiac health.
Main Methods:
- Female zebrafish were fed either a normal diet (6% fat) or HFD (24% fat) for 8 weeks.
- Metabolic function was assessed via glucose tolerance tests and insulin analysis.
- Cardiac function, structural changes, and mitochondrial health were evaluated using echocardiography, histopathology, and molecular assays.
Main Results:
- HFD zebrafish exhibited obesity, insulin resistance, and impaired glucose tolerance.
- Cardiac analysis showed hypertrophy, reduced ejection fraction, and diastolic dysfunction.
- Observed were lipid accumulation, fibrosis, inflammation, impaired mitochondrial respiration, and oxidative stress.
Conclusions:
- A female zebrafish HFD model successfully replicates key features of human DCM.
- This model provides insights into DCM pathogenesis, including metabolic, fibrotic, and mitochondrial aspects.
- The established model is a valuable platform for future DCM mechanistic studies and drug screening.
More Related Videos
Related Concept Videos
Heart Failure II: Pathophysiology
Type II Diabetes I: Introduction
Type II Diabetes II: Pathophysiology

